Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran*

By Oberye J.J.L.   Mannaerts B.M.J.L.   Kleijn H.-J.   Timmer C.J.  

Fertility and Sterility, Vol. 72, Iss. 6, 1999-12 ,pp. : 1001-1005

Elsevier

Access to resources Recommend Favorite

Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon)

By de Jong D.   Macklon N.S.   Eijkemans M.J.C.   Mannaerts B.M.J.L.   Coelingh Bennink H.J.T.   Fauser B.C.J.M.   for the Ganirelix Dose-Finding Study Group  

Fertility and Sterility, Vol. 75, Iss. 4, 2001-04 ,pp. : 688-693

Elsevier

Access to resources Recommend Favorite

Differential dose of antagonist (Ganirelix) relative to exogenous FSH

By Al-Inany H.  

Fertility and Sterility, Vol. 76, Iss. 5, 2001-11 ,pp. : 1080-1080

Elsevier

Access to resources Recommend Favorite

Concurrent ganirelix and follitropin beta therapy is an effective and safe regimen for ovulation induction in women with polycystic ovary syndrome

By Elkind-Hirsch K.E.   Webster B.W.   Brown C.P.   Vernon M.W.  

Fertility and Sterility, Vol. 79, Iss. 3, 2003-03 ,pp. : 603-607

Elsevier

Access to resources Recommend Favorite

Effect of the gonadotropin-releasing hormone antagonist ganirelix on cyclic adenosine monophosphate accumulation of human granulosa-lutein cells

By Demirel L.C.   Weiss J.M.   Polack S.   Unlu C.   Diedrich K.   Ortmann O.  

Fertility and Sterility, Vol. 74, Iss. 5, 2000-11 ,pp. : 1001-1007

Elsevier

Access to resources Recommend Favorite